Research Topics
| A J BustiSummaryAffiliation: Texas Tech University Health Sciences Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Atazanavir for the treatment of human immunodeficiency virus infectionAnthony J Busti
Department of Pharmacy Practice, Texas Tech University Health Sciences Center School of Pharmacy, Dallas Ft Worth Regional Campus, Dallas, Texas, USA
Pharmacotherapy 24:1732-47. 2004..We conclude that atazanavir is a distinctively characteristic protease inhibitor owing to its in vitro potency, once-daily dosing, distinct initial resistance pattern, and infrequent association with metabolic abnormalities...- Tegaserod-induced myocardial infarction: case report and hypothesisAnthony J Busti
School of Pharmacy Dallas Ft Worth Regional Campus, Texas Tech University Health Sciences Center, Dallas, Texas 75216, USA
Pharmacotherapy 24:526-31. 2004..When considering prescribing a drug with 5-HT1 receptor agonist activity, clinicians should review the patient's medical history specifically for the presence of underlying cardiovascular risk factors... - A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patientsA J Busti
Texas Tech University Health Sciences Center School of Pharmacy, Dallas Ft Worth Regional Campus, Dallas, TX 75216, USA
HIV Med 7:317-22. 2006.... 
Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatinAnthony J Busti
School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX 75216, USA
J Cardiovasc Pharmacol 51:605-10. 2008..The objective is to study the pharmacokinetic interaction of RSV with atazanavir/ritonavir (ATV/RTV) or fosamprenavir/ritonavir (FPV/RTV)...- Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healingAnthony J Busti
Texas Tech University Health Sciences Center School of Pharmacy, Dallas Ft Worth Regional Campus, Dallas, Texas 75216, USA
Pharmacotherapy 25:1566-91. 2005..Clinicians must carefully evaluate individual patient risk factors, disease severity, and the pharmacokinetics of available therapies when weighing the risks and benefits of discontinuing therapy in the perioperative setting... - The role of oral direct thrombin inhibitors in the treatment of venous thromboembolismAnthony J Busti
School of Pharmacy, Texas Tech University Health Sciences Center, Dallas Veterans Affairs Medical Center, Dallas, Texas 75216, USA
Pharmacotherapy 24:184S-189S. 2004..Although there is more to learn about ximelagatran, available data suggest that it is likely to be the most significant therapeutic advance in this area in over 50 years... - Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virusSean T Nguyen
Texas Tech University Health Sciences Center School of Pharmacy, Dallas Fort Worth Regional Campus, Dallas, Texas 75216, USA
Pharmacotherapy 28:323-30. 2008.... 
Multicenter evaluation of vancomycin dosing: emphasis on obesityRonald G Hall
Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, Texas, USA
Am J Med 121:515-8. 2008..There is a paucity of data available regarding the dosing of antimicrobials in obesity. However, data are available demonstrating that vancomycin should be dosed on the basis of actual body weight...- A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literatureAmy M Bain
School of Pharmacy, Texas Tech University Health Sciences Center, Dallas Forth Worth Regional Campus, Dallas, Texas 75216, USA
Pharmacotherapy 28:932-8. 2008.... - Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavirAnthony J Busti
Texas Tech University Health Sciences Center School of Pharmacy, Dallas, Texas, USA
J Investig Med 56:539-44. 2008..However, its effects on insulin sensitivity have not been elucidated. We conducted this study to test the hypothesis that ATV improves insulin resistance and dyslipidemia... - Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapyAnita P Rahman
School of Pharmacy, Texas Tech University Health Sciences Center, Dallas Fort Worth Regional Campus, Dallas, Texas 75216, USA
Pharmacotherapy 28:913-9. 2008.... - Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular riskStephen P Motsko
University of Texas at Austin School of Pharmacy, Austin, Texas, USA
Drug Saf 29:621-32. 2006..e. etodolac, nabumetone and salsalate), and selective COX-2 inhibitors... - Additional antiretroviral and immunosuppressive drug-drug interactionsAnthony J Busti
Kidney Int 66:2469; author reply 2469. 2004 - Reteplase in acute myocardial infarctionAnthony J Busti
JAMA 291:2429-30; author reply 2430. 2004 - Ranolazine as add-on therapy for patients with severe chronic anginaJustin S Hooper
JAMA 291:1959; author reply 1959-60. 2004 - Prednisone for chronic obstructive pulmonary diseaseAnthony J Busti
N Engl J Med 349:1288-90; author reply 1288-90. 2003